Combination targeted therapy in advanced renal cell carcinoma.
about
Molecular and immunologic markers of kidney cancer-potential applications in predictive, preventive and personalized medicineA phase I, open-label study of trebananib combined with sorafenib or sunitinib in patients with advanced renal cell carcinomaEverolimus: the first approved product for patients with advanced renal cell cancer after sunitinib and/or sorafenibPhase Ib study of tivozanib (AV-951) in combination with temsirolimus in patients with renal cell carcinoma.Combination therapy: intermittent sorafenib with bevacizumab yields activity and decreased toxicity.Recent updates in renal cell carcinomaA phase I dose-escalation study to evaluate safety and tolerability of sorafenib combined with sirolimus in patients with advanced solid cancer.Vertical targeting of the phosphatidylinositol-3 kinase pathway as a strategy for treating melanoma.A phase 2 trial of dasatinib in advanced melanoma.A phase Ib study of combined VEGFR and mTOR inhibition with vatalanib and everolimus in patients with advanced renal cell carcinomaTherapeutic advances in women's cancersFDA drug approval summary: bevacizumab plus interferon for advanced renal cell carcinoma.Phase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinoma.The VHL/HIF axis in clear cell renal carcinoma.Endothelial follicle stimulating hormone receptor in primary kidney cancer correlates with subsequent response to sunitinib.A prospective phase II study of 2-methoxyestradiol administered in combination with bevacizumab in patients with metastatic carcinoid tumors.The expression and role of tyrosine kinase ETK/BMX in renal cell carcinomaAntiangiogenic treatments and mechanisms of action in renal cell carcinoma.Sorafenib for the treatment of renal cancer.The role of prostaglandin E2 in renal cell cancer development: future implications for prognosis and therapy.Characterization and targeting of phosphatidylinositol-3 kinase (PI3K) and mammalian target of rapamycin (mTOR) in renal cell cancerEvaluation of changes in the tumor microenvironment after sorafenib therapy by sequential histology and 18F-fluoromisonidazole hypoxia imaging in renal cell carcinomaCombination of Temsirolimus and tyrosine kinase inhibitors in renal carcinoma and endothelial cell lines.Discovery of a highly potent, orally active mitosis/angiogenesis inhibitor r1530 for the treatment of solid tumors.
P2860
Q26779144-4FB16CFF-AC3B-4B62-BBD5-E8B324B1268EQ28304566-85D3D350-D6A1-4B2B-B00E-8D615FE91866Q28765488-4985F2D8-32F7-418E-BE30-A65161B5FB16Q33408127-56737FCB-02B9-4EE8-BEB0-79D7001F0061Q33658626-65C2DEBD-D877-43F1-B59E-376996B3B072Q34003369-8259D868-3782-4983-B39E-34B2323DF144Q34363435-471F0489-5CAF-4C89-BF49-F1D8AD1E9BF2Q34682072-17C5AFE6-298D-4D60-B999-5349E2B4A511Q35048145-227F421F-71C0-4289-8AA2-2B6840AF7669Q35135727-A84F5293-EE7C-4D04-BABD-BEF41226F6ACQ35418973-7D6FD06C-65B8-4BD2-82FD-80C8F83D648BQ35583662-49F75C39-F682-4E5C-BBF4-6CC1C70997ABQ36718942-6D77E635-0208-4672-928A-E06282A4BC84Q36872295-28636513-629D-4089-B9C1-EE7302CFD77FQ37294895-CA5F4187-A119-4EEE-AFA4-092E00D66D40Q37640526-B265EDB4-4A21-4B35-A948-C97789CAD546Q37699758-B6BA717C-24ED-400F-BA06-4C73D02A17F3Q37875792-EACD14BB-37A0-438C-A2D0-5AEDAEBE16DEQ37977494-64CA483A-053C-4158-A5E1-3017E0586DB6Q38282450-F44CD8BD-4133-4E5E-ACAD-56E35C09E675Q38425940-99DEFD2F-E6DE-4EAB-8A1D-AF6CDB45EC40Q39281721-38B5BD36-E0AE-49A7-9C84-4C78057CA076Q39398836-6A8818A3-220A-4636-A671-F87B43EA6C33Q39779399-06247D40-DF49-490E-A46F-5B9B092D63DD
P2860
Combination targeted therapy in advanced renal cell carcinoma.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on May 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Combination targeted therapy in advanced renal cell carcinoma.
@en
Combination targeted therapy in advanced renal cell carcinoma.
@nl
type
label
Combination targeted therapy in advanced renal cell carcinoma.
@en
Combination targeted therapy in advanced renal cell carcinoma.
@nl
prefLabel
Combination targeted therapy in advanced renal cell carcinoma.
@en
Combination targeted therapy in advanced renal cell carcinoma.
@nl
P356
P1433
P1476
Combination targeted therapy in advanced renal cell carcinoma.
@en
P2093
Igor Puzanov
Jeffrey Sosman
P304
P356
10.1002/CNCR.24234
P407
P433
P577
2009-05-01T00:00:00Z